ACECLOFENAC INJECTION FORMULATION FILETYPE PDF
The formulation containing HPMC K15MCR and Polyox WSR at the Sorry, there is no online preview for this file type. Ranitidine can be found in many pharmaceutical firms such as tablets, injectable solutions and oral Dissolution enhancement of aceclofenac tablet by solid dispersion technique. short biological half life demands continuous intravenous infusion or time spaced injection. We chose tristearin as solid lipid and formulated it in nanoparticulate form by an ultrasonic Sorry, there is no online preview for this file type. Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Injectable. Moderate. REACTION TO SEPTRIN PROPHYLAXIS IN A NEWLY STARTED SWEATING WITH CHANGE IN HAEMODYNAMIC STABILITY. 1. 1 Injectable. Mild. 2. ORAL DICLOFENAC 50MG, HAEMOPTYSIS.
|Published (Last):||3 January 2016|
|PDF File Size:||2.35 Mb|
|ePub File Size:||3.31 Mb|
|Price:||Free* [*Free Regsitration Required]|
Such compositions can also be used to treat fibrosis that occurs with radiation therapy. In contrast, the acute gastric ulcerogenic activity of aceclofenac was about 2, 4 and 7-fold lesser than that of naproxen, diclofenac, or indometacin, respectively. Thus, the same solution can be used for lyophilization within 4 h and 12 h, respectively, under unavoidable conditions.
The compositions disclosed in the present invention are stable upon storage at room temperature and at refrigerated temperatures.
The volume can be from 5gm to gm. Another object of the present invention is to provide NSAID liquid parenteral formulation that does not require dilution or mixing or reconstitution immediately prior to use.
However, aceclofenac acecloenac practically insoluble in water, freely soluble in acetone and soluble in alcohol. The stable injectable pharmaceutical composition of the present invention as prepared in example 2 was subjected to stability studies before lyophilization and the results are shown in table 3.
It should be emphasized that the above- described embodiments of aceclofennac present invention, particularly any “preferred” embodiments, are merely possible examples of the invention of implementations, merely set forth for a clear understanding of the principles of the invention. Such compositions are useful in treating pain and inflammation in such diseases as migraine headaches, periarteritis, thyroiditis, aplastic anemia, Hodgkin’s disease, scleroderma, rheumatic fever, type 1 diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet’s syndrome, polymyositis, gingivitis, nephritis, hypersensitivity, swelling occurring after fjletype including brain edema, myocardial ischemia, and the like.
The vials were shaken mechanically for 12 h at room temperature in an orbital flask shaker Khera Instruments Pvt. The Aceclofenac formulation of Item 1, wherein said formulation further comprises one or more salicylic acid derivatives as stabilizer component and other optional Aceclofenac salt stabilizer component comprising oxygen limiting means.
The results also showed a trend towards a better safety and tolerability profile of aceclofenac over diclofenac resinate from a clinical point of view. Author information Article notes Copyright and License information Disclaimer.
Such compositions are useful in prevention and treatment of pain and inflammation caused by benign and malignant tumors and neoplasia including cancer, such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia epithelial carcinoma such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin cancer such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body.
Further, these tubes can be printed in multi-color elegantly. It is practically insoluble in water. It is also, to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Titrimetric analysis of aceclofenac in tablets using hydrotropic solubilization technique. Further object of the present invention is to provide Aceclofenac injection which has better safety and tolerability profile as compared to Diclofenac from the clinical point of view.
Rajkumar Gupta – Google+
Table 1 Hydrotropic blends selected for aceclofenac. Possible spectroscopic changes fromulation the structure of aceclofenac in the presence of hydrotropes were subsequently investigated. Novel application of hydrotropic solubilization in the spectrophotometric analysis of tinidazole in dosage form.
Marketed formulation Zynec injection.
US20090156670A1 – Nonaqueous liquid parenteral aceclofenac formulation – Google Patents
Aceclofenac was mixed to it under stirring and dissolved to obtain clear solution. The present invention utilizes arginine or its pharmaceutically acceptable salt forms, preferably L-arginine or arginine hydrochloride, more preferably L-arginine for solubilization. Then, the plate was left for 10 min to be dried and transferred to a solvent jar saturated with solvent system composed of mixture of chloroform, methanol and ammonia solution Quantitative analysis of hydrochlorothiazide tablets using lignocaine hydrochloride as hydrotropic agent.
The present compositions can be used in combination therapies with opioids and other analgesics, including narcotic analgesics, Mu receptor antagonists, Kappa fomrulation antagonists, non-narcotic i. A stable injectable pharmaceutical composition comprising an aqueous solution of arginine and aceclofenac in the molar ratio of arginine to aceclofenac in the range of about 1. Hydrotropic solubilization process involves cooperative intermolecular interaction with several balancing molecular forces, rather than either a specific complexation event or a process dominated by a medium effect, such as co-solvency or salting-in.
The salicylic acid derivative component of the present invention helps to stabilize the injection formulatlon improve efficiency.
USA1 – Nonaqueous liquid parenteral aceclofenac formulation – Google Patents
The results as shown in table 4 indicate that formulatkon the molar ratio of arginine to aceclofenac is 0. Limitations in using non aqueous solvents for injectable compositions include possible drug precipitation, pain, inflammation and hemolysis upon injection. As specified in 21 CFR Although any ijjection and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described.
Compositions of the invention, whether ready-to-use or requiring dilution prior to administration, can be prepared by processes that avoid the need for an expensive and time consuming lyophilization step. A control sample fi,etype in a sealed vial was also weighed by measuring the increase in weight at room temperature